All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Zanubrutinib Yields High Response Rates in Japanese Patients With CLL/SLL and Waldenström Macroglobulinemia

May 25th 2025

Zanubrutinib showed high response rates and durable responses among Japanese patients with CLL/SLL and Waldenström macroglobulinemia.

Five Under 5: Top Oncology Videos for the Week of 5/18

May 25th 2025

The top 5 OncLive videos of the week cover insights in HER2+ breast cancer, myeloma, pancreatic cancer, prostate cancer, and sarcoma.

The OncFive: Top Oncology Articles for the Week of 5/18

May 24th 2025

FDA’s ODAC voted on therapeutic approaches in lymphoma, bladder, prostate, and myeloma, and more from OncLive this week.

Post Hoc Data Show Anemia Benefits, Reduced Transfusion Burden With Momelotinib in Myelofibrosis

May 24th 2025

Momelotinib was associated with anemia benefits and reduced transfusion burden in myelofibrosis in a post hoc analysis of 4 trials.

Alana Welm, PhD, Named Chair of Oncological Sciences in the Spencer Fox Eccles School of Medicine at the University of Utah

May 23rd 2025

Alana Welm, PhD, is now the chair of the Department of Oncological Sciences in the Spencer Fox Eccles School of Medicine at the University of Utah.

Inavolisib Plus Palbociclib/Fulvestrant Earns Positive CHMP Opinion for PIK3CA-Mutated, ER+/HER2– Advanced Breast Cancer

May 23rd 2025

The EMA’s CHMP has recommended the approval of inavolisib plus palbociclib/fulvestrant in PIK3CA-mutated, ER-positive advanced breast cancer.

CHMP Recommends EU Approval of Obe-Cel for Relapsed/Refractory B-ALL

May 23rd 2025

The EMA’s CHMP has recommended the approval of obecabtagene autoleucel for adult patients with relapsed/refractory B-ALL.

Updated STARGLO Data Show Maintained OS Benefit With Glofitamab Plus Chemo in R/R DLBCL

May 23rd 2025

Two-year follow-up data continued to show an overall survival benefit with glofitamab plus chemotherapy in relapsed/refractory DLBCL.

Belantamab Mafodotin Combos Approach EU Approval for R/R Multiple Myeloma

May 23rd 2025

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of belantamab mafodotin (Blenrep) in adult patients with relapsed or refractory multiple myeloma.

Mirdametinib Earns Positive CHMP Opinion for NF1-Associated Plexiform Neurofibromas

May 23rd 2025

The EMA’s CHMP has issued a positive opinion for mirdametinib for pediatric and adult patients with NF1-associated plexiform neurofibromas.

Liso-Cel and Pirtobrutinib Add Options in R/R CLL, Underscoring the Importance of Proper Treatment Selection

May 23rd 2025

Seema A. Bhat, MD, discusses the current treatment landscape of chronic lymphocytic leukemia in light of the FDA approvals of liso-cel and pirtobrutinib.

Researchers Address the Barriers to Remote Breast Cancer Symptom Monitoring in the US

May 23rd 2025

Barriers in utilizing remote collection of patient-reported outcomes persist, although it has been proven to be effective in breast cancer.

OncLive Polls Reveal Picks for Top Gastrointestinal Cancer Abstracts at ASCO 2025

May 23rd 2025

GI cancer experts rank key abstracts of interest from the upcoming ASCO Annual Meeting on OncLive’s social media.

Inavolisib Plus Palbociclib and Fulvestrant Improves OS in PIK3CA-Mutant, HR+/HER2– Breast Cancer

May 22nd 2025

Inavolisib plus palbociclib and fulvestrant improved OS in PIK3CA-mutant, HR-positive, HER2-negative, endocrine-resistant advanced breast cancer.

First-Line Maintenance Lurbinectedin Plus Atezolizumab Boosts Survival in ES-SCLC

May 22nd 2025

IMforte data highlight potential for lurbinectedin plus atezolizumab to become a new SOC for first-line maintenance treatment in ES-SCLC.

AI-Assisted Training Improves IHC Interpretation, Classification of HER2-Low and HER2-Ultralow Breast Cancer

May 22nd 2025

AI-assisted training of pathologists enhanced the accuracy of HER2 IHC scoring, potentially expanding eligibility for HER2-targeted treatments.

GLP-1 Agonists Are Linked to Modest Decrease in Obesity-Related Cancers in Adults With Diabetes

May 22nd 2025

The use of GLP-1 agonists was not associated with higher cancer rates and led to a decrease in obesity-related cancers in adults with diabetes.

Olutasidenib Displays High Response Rates in IDH1-Mutated AML Arising From a Prior Myeloproliferative Neoplasm

May 22nd 2025

Olutasidenib was effective both as monotherapy and in combination with azacitidine in patients with IDH1-mutated AML arising from an MPN.

Artificial Intelligence Proves Its Worth in Cancer Treatment, Drug Development, and Other Real-World Applications

May 22nd 2025

Multiple experts on artificial intelligence in cancer care discuss its ever-expanding role in several areas of oncology.

CPRIT Awards over $21 Million to MD Anderson for Cancer Research and Faculty Recruitment

May 22nd 2025

CPRIT awards over $21 million to MD Anderson for cancer research and faculty recruitment.